These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

227 related articles for article (PubMed ID: 32602129)

  • 1. Validation of global item for assessing impact on quality of life of patients with hidradenitis suppurativa.
    Kirby JS; Hereford B; Thorlacius L; Villumsen B; Ingram JR; Garg A; Butt M; Esmann S; King T; Tan J; Jemec GBE
    Br J Dermatol; 2021 Apr; 184(4):681-687. PubMed ID: 32602129
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Convergent Validity of Suffering and Quality of Life as Measured by The Hidradenitis Suppurativa Quality of Life.
    Kursawe Larsen C; Kjaersgaard Andersen R; Kirby JS; Tan J; Saunte DML; Jemec GBE
    J Eur Acad Dermatol Venereol; 2021 Jul; 35(7):1577-1581. PubMed ID: 33539563
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Severity and Area Score for Hidradenitis (SASH): a novel outcome measurement for hidradenitis suppurativa.
    Kirby JS; Butt M; King T
    Br J Dermatol; 2020 Apr; 182(4):940-948. PubMed ID: 31233623
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Measurement properties of the patient global assessment numerical rating scale in moderate-to-severe psoriasis.
    Yu N; Peng C; Zhou J; Gu J; Xu J; Li X; Bi X; Deng H; Li X; Ding Y; Shi Y
    Br J Dermatol; 2023 Sep; 189(4):437-446. PubMed ID: 37310289
    [TBL] [Abstract][Full Text] [Related]  

  • 5. The Hidradenitis Suppurativa Quality of Life (HiSQOL) score: development and validation of a measure for clinical trials.
    Kirby JS; Thorlacius L; Villumsen B; Ingram JR; Garg A; Christensen KB; Butt M; Esmann S; Tan J; Jemec GBE
    Br J Dermatol; 2020 Aug; 183(2):340-348. PubMed ID: 31705538
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Validity of EQ-5D-5L, Skindex-16, DLQI and DLQI-R in patients with hidradenitis suppurativa.
    Gergely LH; Gáspár K; Brodszky V; Kinyó Á; Szegedi A; Remenyik É; Kiss NF; Bató A; Péntek M; Gulácsi L; Sárdy M; Bánvölgyi A; Wikonkál N; Rencz F
    J Eur Acad Dermatol Venereol; 2020 Nov; 34(11):2584-2592. PubMed ID: 32618022
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Assessing the validity, responsiveness and meaningfulness of the Hidradenitis Suppurativa Clinical Response (HiSCR) as the clinical endpoint for hidradenitis suppurativa treatment.
    Kimball AB; Jemec GB; Yang M; Kageleiry A; Signorovitch JE; Okun MM; Gu Y; Wang K; Mulani P; Sundaram M
    Br J Dermatol; 2014 Dec; 171(6):1434-42. PubMed ID: 25040429
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Electronic Patient-Reported Outcomes in Hidradenitis Suppurativa: Content Validity and Usability of the Electronic Hidradenitis Suppurativa Symptom Daily Diary, Hidradenitis Suppurativa Symptom Questionnaire, and Hidradenitis Suppurativa Quality of Life Questionnaire.
    Ingram JR; Ciaravino V; Rolleri R; Pansar I; Dias-Barbosa C; Kirby JS
    Dermatology; 2024; 240(1):65-76. PubMed ID: 37820596
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Development and initial validation of the HS-IGA: a novel hidradenitis suppurativa-specific investigator global assessment for use in interventional trials.
    Garg A; Zema C; Kim K; Gao W; Chen N; Jemec GBE; Kirby J; Thorlacius L; Villumsen B; Ingram JR
    Br J Dermatol; 2022 Aug; 187(2):203-210. PubMed ID: 35599448
    [TBL] [Abstract][Full Text] [Related]  

  • 10. HIDRAdisk: validation of an innovative visual tool to assess the burden of hidradenitis suppurativa.
    Peris K; Lo Schiavo A; Fabbrocini G; Dini V; Patrizi A; Fusano M; Bianchi L; Guanziroli E; Guarneri C; Parodi A; Bertoldi A; Musumeci ML; Offidani A; Rongioletti F; Pistone G; Malara G; Potenza C; Casari A; Franchi C; Ardigò M; Cusano F; Stingeni L; Amerio P; Mancini LL; Prignano F; Deboli T; Gualberti G; Saragaglia V; Bettoli V
    J Eur Acad Dermatol Venereol; 2019 Apr; 33(4):766-773. PubMed ID: 30633405
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Two Cases of Hidradenitis Suppurativa Treated with Adalimumab at the Department of Dermatology and Venereology, Clinical Hospital Mostar.
    Lovrić I; Brkić J; Ćorluka M; Čović M; Pejić J; Zeljko Penavić J
    Acta Dermatovenerol Croat; 2021 Jul; 29(2):108-110. PubMed ID: 34477078
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Hidradenitis Suppurativa Quality of Life (HiSQOL): creation and validation of the Polish language version.
    Krajewski PK; Matusiak Ł; Szepietowska M; Rymaszewska JE; Jemec GBE; Kirby JS; Szepietowski JC
    Postepy Dermatol Alergol; 2021 Dec; 38(6):967-972. PubMed ID: 35126002
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Validation of the Hidradenitis Suppurativa Investigator Global Assessment: A Novel Hidradenitis Suppurativa-Specific Investigator Global Assessment for Use in Interventional Trials.
    Garg A; Zema C; Ciaravino V; Rolleri R; Peterson L; Garcia L; Massaro T; Jemec GBE; Kirby JS; Thorlacius L; Ingram JR
    JAMA Dermatol; 2023 Jun; 159(6):606-612. PubMed ID: 37099284
    [TBL] [Abstract][Full Text] [Related]  

  • 14. The Burden of Hidradenitis Suppurativa Signs and Symptoms in Quality of Life: Systematic Review and Meta-Analysis.
    Montero-Vilchez T; Diaz-Calvillo P; Rodriguez-Pozo JA; Cuenca-Barrales C; Martinez-Lopez A; Arias-Santiago S; Molina-Leyva A
    Int J Environ Res Public Health; 2021 Jun; 18(13):. PubMed ID: 34206415
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Quality of life measurement in hidradenitis suppurativa: position statement of the European Academy of Dermatology and Venereology task forces on Quality of Life and Patient-Oriented Outcomes and Acne, Rosacea and Hidradenitis Suppurativa.
    Chernyshov PV; Zouboulis CC; Tomas-Aragones L; Jemec GB; Svensson A; Manolache L; Tzellos T; Sampogna F; Pustisek N; van der Zee HH; Marron SE; Spillekom-van Koulil S; Bewley A; Linder D; Abeni D; Szepietowski JC; Augustin M; Finlay AY
    J Eur Acad Dermatol Venereol; 2019 Sep; 33(9):1633-1643. PubMed ID: 31037773
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Hidradenitis Suppurativa Quality of Life 24 (HSQoL-24) now available for Polish patients: creation and validation of the Polish language version.
    Krajewski PK; Bardowska K; Matusiak Ł; Szepietowska M; Tyczyńska K; Marron SE; Tomas Aragones L; Szepietowski JC
    Postepy Dermatol Alergol; 2022 Dec; 39(6):1053-1058. PubMed ID: 36686006
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Reliability of the hidradenitis suppurativa clinical response in the assessment of patients with hidradenitis suppurativa.
    Kimball AB; Ganguli A; Fleischer A
    J Eur Acad Dermatol Venereol; 2018 Dec; 32(12):2254-2256. PubMed ID: 29959796
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Could Residents Adequately Assess the Severity of Hidradenitis Suppurativa? Interrater and Intrarater Reliability Assessment of Major Scoring Systems.
    Włodarek K; Stefaniak A; Matusiak Ł; Szepietowski JC
    Dermatology; 2020; 236(1):8-14. PubMed ID: 31487719
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Quality of Life in Hidradenitis Suppurativa: An Update.
    Chernyshov PV; Finlay AY; Tomas-Aragones L; Poot F; Sampogna F; Marron SE; Zemskov SV; Abeni D; Tzellos T; Szepietowski JC; Zouboulis CC
    Int J Environ Res Public Health; 2021 Jun; 18(11):. PubMed ID: 34204126
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Item-specific patterns of the Skindex-17 in individuals with different levels of Hidradenitis Suppurativa severity: a network analysis study.
    Raimondi G; Samela T; Fania L; Abeni D
    Front Public Health; 2023; 11():1284365. PubMed ID: 38026379
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 12.